Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cullinan Management (CGEM)
NASDAQ:CGEM
RESEARCH TOOLSreports
Holding CGEM?
Track your performance easily
CGEM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.50 - $30.19
Previous CloseN/A
Volume73.34K
Average Volume (3M)539.25K
Market Cap
$614.30M
Enterprise Value$400.93M
Total Cash (Recent Filing)$33.83M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Mar 06, 2025EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding58,227,592
10 Day Avg. Volume597,868
30 Day Avg. Volume539,252
Standard Deviation0.17
R-Squared0.00153
Alpha-0.00977
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1228.60
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue801.86
Enterprise Value/Gross Profit801.86
Enterprise Value/Ebitda-2.14
Forecast
1Y Price Target
$33.67Price Target Upside218.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Cullinan Management News
PremiumCompany Announcements
Cullinan Management Achieves Milestone in Cancer Trial
PremiumCompany Announcements
Cullinan Therapeutics Announces Q3 2024 Progress and Outlook
Bulls Say, Bears Say
Bulls Say
Clinical Advancements'978 induced T cell activation, B cell killing, and cytokine production in human peripheral blood mononuclear cells from healthy volunteers and patients with SLE or RA.
Financial PerformanceRaising the price target to $34 from $29 based on the progress and expectations from the clinical trials.
Regulatory ApprovalCullinan's IND applications for '978 in patients with moderate to severe systemic lupus erythematosus (SLE) was cleared in the US and Australia.
Bears Say
Financial PerformanceCullinan is decreasing its FY24 EPS estimate, indicating potential financial performance concerns.
Regulatory And Commercial RisksRisks include commercial, regulatory, development, manufacturing, financial/dilution, and liability challenges.
Stock DilutionRisks include financial/dilution challenges, which may impact shareholder value.
---
Ownership Overview
6.96% Insiders
12.29% Mutual Funds
0.28% Other Institutional Investors
65.53% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CGEM FAQ
What was Cullinan Management’s price range in the past 12 months?
Cullinan Management lowest stock price was $9.50 and its highest was $30.19 in the past 12 months.
What is Cullinan Management’s market cap?
Cullinan Management’s market cap is $614.30M.
When is Cullinan Management’s upcoming earnings report date?
Cullinan Management’s upcoming earnings report date is Mar 06, 2025 which is in 32 days.
How were Cullinan Management’s earnings last quarter?
Cullinan Management released its earnings results on Nov 07, 2024. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.788 by $0.098.
Is Cullinan Management overvalued?
According to Wall Street analysts Cullinan Management’s price is currently Undervalued.
Does Cullinan Management pay dividends?
Cullinan Management does not currently pay dividends.
What is Cullinan Management’s EPS estimate?
Cullinan Management’s EPS estimate is -0.79.
How many shares outstanding does Cullinan Management have?
Cullinan Management has 58,227,592 shares outstanding.
What happened to Cullinan Management’s price movement after its last earnings report?
Cullinan Management reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.788. Following the earnings report the stock price went down -5.461%.
Which hedge fund is a major shareholder of Cullinan Management?
Currently, no hedge funds are holding shares in CGEM
---
Cullinan Management Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.67 (218.84% Upside)
$33.67 (218.84% Upside)
Blogger Sentiment
Bullish
CGEM Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 750.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $289.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.60%
12-Months-Change
Fundamentals
Return on Equity
-26.18%
Trailing 12-Months
Asset Growth
32.05%
Trailing 12-Months
Company Description
Cullinan Management
Cullinan Management Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
---
CGEM Stock 12 Month Forecast
Average Price Target
$33.67
▲(218.84% Upside)
Technical Analysis
Editas Medicine
―
Crispr Therapeutics AG
―
Kiniksa Pharmaceuticals
―
Allogene Therapeutics
―
Foghorn Therapeutics
―
Best Analysts Covering CGEM
1 Year
1 Year Success Rate
10/28 ratings generated profit
1 Year Average Return
+1.22%
reiterated a buy rating 4 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of +1.22% per trade.
---